Home / Health / Court Seeks Contempt Response on Drug Approvals
Court Seeks Contempt Response on Drug Approvals
18 Mar
Summary
- Court seeks response on contempt plea against drug regulator.
- Plea concerns approval process for GLP-1 class weight loss drugs.
- Regulator allegedly failed to act on drug approval concerns since July 2025.
A contempt petition has been filed against India's drug regulator, prompting the Delhi High Court to seek a response. The plea, initiated by a health influencer, alleges that the regulator has not addressed concerns regarding the approval of GLP-1 class drugs, which include popular weight loss medications.
The court previously directed the regulator in July 2025 to decide on the submitted representations within three months. However, the petitioner asserts that no decision has been communicated, rendering the court's earlier directive ineffective and allowing regulatory uncertainty to persist.
The concerns raised encompass the waiver of India-specific clinical trials, gaps in drug safety monitoring, and inconsistent regulatory practices. The next court hearing is scheduled for May 21, with all parties awaiting the regulator's formal response.
